Amanote Research
Register
Sign In
Inhaled Short Acting Beta Agonist Use in COPD and the Risk of Acute Myocardial Infarction
Thorax
- United Kingdom
doi 10.1136/thorax.58.1.43
Full Text
Open PDF
Abstract
Available in
full text
Categories
Pulmonary
Respiratory Medicine
Date
January 1, 2003
Authors
S Suissa
Publisher
BMJ
Related search
Inhaled Beta-2-Agonists/Muscarinic Antagonists and Acute Myocardial Infarction in COPD Patients
Respiratory Medicine
Pulmonary
Respiratory Medicine
Effective Management of COPD in Primary Care — The Role of Long-Acting Beta Agonist/Inhaled Corticosteroid Combination Therapy
Primary Care Respiratory Journal
The Risk of Acute Myocardial Infarction
Epidemiology
Epidemiology
Effects of Roflumilast in COPD Patients Receiving Inhaled Corticosteroid/Long-Acting Β2-Agonist Fixed-Dose Combination: RE2SPOND Rationale and Study Design
International Journal of COPD
Environmental
Public Health
Health Policy
Medicine
Pulmonary
Respiratory Medicine
Occupational Health
Marijuana Use and Short-Term Outcomes in Patients Hospitalized for Acute Myocardial Infarction
PLoS ONE
Multidisciplinary
Use of Anticoagulants in Acute Myocardial Infarction
Circulation
Cardiovascular Medicine
Physiology
Cardiology
Severe Exacerbation and Pneumonia in COPD Patients Treated With Fixed Combinations of Inhaled Corticosteroid and Long-Acting Beta2 Agonist
International Journal of COPD
Environmental
Public Health
Health Policy
Medicine
Pulmonary
Respiratory Medicine
Occupational Health
Use of Statins and Beta-Blockers After Acute Myocardial Infarction According to Income and Education
Journal of Epidemiology and Community Health
Epidemiology
Public Health
Occupational Health
Environmental
PRS30 Inhaled Corticosteroid and Long-Acting Beta-Agonist Medication Compliance in Patients With Moderate and Severe Asthma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
